Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 19/20 | 0.50 |
| ▸ | ESR1 | P03372 | 7/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11714739 | 0.79 | ESR2 (0.58) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL31574451 | 0.79 | ESR2 (0.58) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL17850375 | 0.79 | SLC6A4 (0.44) | — | |
| SCHEMBL1206040 | 0.79 | SLC6A2 (0.54) | — | |
| SCHEMBL9911019 | 0.79 | SLC6A4 (0.55) | CHRNB4CHRNA3 | |
| SCHEMBL1206038 | 0.79 | SLC6A2 (0.54) | — | |
| SCHEMBL1335714 | 0.79 | SLC6A4 (0.44) | — | |
| SCHEMBL1335712 | 0.79 | SLC6A4 (0.44) | — | |
| SCHEMBL12093044 | 0.78 | KDM1A (0.53) | — | |
| SCHEMBL6227963 | 0.78 | KDM1A (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | ESR2 740/4885ESR1 840/4885CYP3A4 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.